Data availability
muscle-invasive urothelial carcinoma
Qualified researchers may request Ono Pharmaceutical Co., Ltd. to disclose individual patient-level data from clinical studies through the following website: Prior publication: The overall results of CheckMate 274 were published as Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102–14. Results of this analysis were presented at the 109th Annual Meeting of the Japanese Urological Association, December 7–9, 2021 (Yokohama, Japan).